Citius Oncology (CTOR) & Its Competitors Financial Comparison

Citius Oncology (NASDAQ:CTOR) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its rivals? We will compare Citius Oncology to related businesses based on the strength of its profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Insider and Institutional Ownership

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 6.7% of Citius Oncology shares are owned by insiders. Comparatively, 13.5% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Citius Oncology and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1	0	2	0	2.33
Citius Oncology Competitors	6814	12514	38253	1219	2.58

Citius Oncology currently has a consensus target price of $6.00, suggesting a potential upside of 455.56%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 56.51%. Given Citius Oncology’s higher possible upside, analysts plainly believe Citius Oncology is more favorable than its rivals.

Profitability

This table compares Citius Oncology and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-65.79%	-26.15%
Citius Oncology Competitors	-824.61%	-115.98%	-28.88%

Earnings & Valuation

This table compares Citius Oncology and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Citius Oncology	N/A	-$24.76 million	-3.18
Citius Oncology Competitors	$965.22 million	-$38.49 million	10.17

Citius Oncology’s rivals have higher revenue, but lower earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Citius Oncology has a beta of 3.09, meaning that its share price is 209% more volatile than the S&P 500. Comparatively, Citius Oncology’s rivals have a beta of 0.96, meaning that their average share price is 4% less volatile than the S&P 500.

Summary

Citius Oncology beats its rivals on 8 of the 13 factors compared.

About Citius Oncology

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.